What is Lifesci Capital’s Forecast for Oculis Q2 Earnings?

Oculis Holding AG (NASDAQ:OCS) – Research analysts at Lifesci Capital increased their Q2 2026 earnings per share (EPS) estimates for Oculis in a report issued on Tuesday, May 12th. Lifesci Capital analyst P. Dolezal now anticipates that the company will post earnings of ($0.45) per share for the quarter, up from their prior forecast of ($0.47). The consensus estimate for Oculis’ current full-year earnings is ($2.17) per share. Lifesci Capital also issued estimates for Oculis’ Q3 2026 earnings at ($0.47) EPS, Q4 2026 earnings at ($0.48) EPS and FY2026 earnings at ($2.02) EPS.

Oculis (NASDAQ:OCS) last issued its earnings results on Monday, May 11th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.14). Oculis had a negative net margin of 8,460.67% and a negative return on equity of 56.78%. The company had revenue of $0.26 million during the quarter, compared to analyst estimates of $0.25 million.

OCS has been the subject of a number of other reports. HC Wainwright lifted their target price on Oculis from $44.00 to $47.00 and gave the company a “buy” rating in a research note on Tuesday. Stifel Nicolaus lifted their target price on Oculis from $40.00 to $50.00 and gave the company a “buy” rating in a research note on Wednesday, March 4th. Wall Street Zen downgraded Oculis from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oculis in a research report on Tuesday, April 21st. Finally, Needham & Company LLC boosted their price objective on Oculis from $40.00 to $46.00 and gave the stock a “buy” rating in a research report on Tuesday. Seven analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Oculis presently has a consensus rating of “Moderate Buy” and an average price target of $45.14.

Oculis Stock Performance

Shares of OCS stock opened at $31.37 on Thursday. The company has a quick ratio of 5.96, a current ratio of 5.18 and a debt-to-equity ratio of 0.01. The business has a 50 day moving average of $27.25 and a two-hundred day moving average of $24.47. Oculis has a 52 week low of $16.00 and a 52 week high of $34.47. The company has a market cap of $1.82 billion, a P/E ratio of -14.73 and a beta of 0.38.

Institutional Investors Weigh In On Oculis

Several hedge funds and other institutional investors have recently added to or reduced their stakes in OCS. Himension Capital Singapore PTE. LTD. bought a new position in shares of Oculis in the first quarter valued at $503,000. Koshinski Asset Management Inc. bought a new position in shares of Oculis in the first quarter valued at $238,000. Y Intercept Hong Kong Ltd bought a new position in shares of Oculis in the first quarter valued at $776,000. Perceptive Advisors LLC bought a new position in shares of Oculis in the fourth quarter valued at $9,862,000. Finally, Millennium Management LLC bought a new position in shares of Oculis in the fourth quarter valued at $312,000. Institutional investors own 22.30% of the company’s stock.

Key Stories Impacting Oculis

Here are the key news stories impacting Oculis this week:

• Positive Sentiment: Needham raised its price target on Oculis to $46 from $40 and maintained a buy rating, implying meaningful upside from current levels. Oculis (NASDAQ:OCS) Price Target Raised to $46.00 at Needham & Company LLC
• Positive Sentiment: HC Wainwright increased its price target to $47 from $44 and kept a buy rating, while also slightly improving near-term earnings estimates. HC Wainwright Issues Positive Forecast for Oculis (NASDAQ:OCS) Stock Price
• Positive Sentiment: HC Wainwright and Lifesci Capital both nudged 2026 quarterly EPS estimates higher, suggesting analysts expect Oculis’ losses to be slightly smaller than previously projected.
• Neutral Sentiment: Lifesci Capital lowered its FY2026 EPS estimate to a loss of $2.02 per share, which still reflects continued unprofitability but is close to consensus.
• Negative Sentiment: Despite the estimate revisions, Oculis remains loss-making, and recent earnings history showed a wider-than-expected quarterly loss, which can limit the stock’s upside if execution disappoints.

Oculis Company Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.